Contra-indicated in women who are or may become pregnant.
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAME: Zytiga (Janssen Biotech)
- INDICATIONS: Metastatic castration-resistant prostate cancer (in combination with prednisone)
- CLASS: CYP17 inhibitor, Enzyme inhibitor
- HALF-LIFE: 12 hours
- FDA APPROVAL DATE: 04/28/2011
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Atazanavir, Carbamazepine, Clarithromycin, CYP3A4 inducers or inhibitors, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, Ritonavir, Saquinavir, Telithromycin, Thioridazine, Voriconazole
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of abiraterone in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 03/28/2025
